Strategic alliance The company merged with Decode Health in May 2022, forming a combined entity. This indicates potential cross-sell opportunities for integrated data analytics, health IT solutions, and services that leverage both organizations' capabilities.

Clinical data edge With a focus on RNA analysis and diagnostic tests like Isolate Fibromyalgia, there is potential to expand into additional molecular diagnostics, biomarkers, and precision medicine offerings for health systems and specialty clinics.

Resource profile Small team size (2-10 employees) suggests a lean operation with high reliance on partnerships and channel channels. A sales approach could emphasize scalable, low-friction deployments and managed services.

Growth potential Recent funding of six figures and revenues in the mid single to low double digits indicate room for expansion; targeted opportunities with mid to large hospitals and diagnostics labs could accelerate revenue growth.

Competitive landscape Operating alongside large, established players in the diagnostics and health IT space; positioning as a nimble innovator with cutting-edge RNA-based tests can help win pilot programs and strategic contracts.